Larger VC Deals Could Become More Common In Devices

Big venture capital investments … scratch that … really big venture capital investments catch our attention these days. After all, venture capital firms are slowly beginning to fade away, and the pool of venture capital is said to be drying up with it. So we tend to sit up and take notice when a company like personalized knee implant manufacturer ConforMIS Inc. raises $89 million as it did last month. (SeeAlso see "ConforMIS Gets Personal With $89 Million Round" - Medtech Insight, 27 February, 2012..) [See Deal] ConforMIS, in raising the fund, actually turned to institutional investors rather than just VCs for the money it needs to launch its new total knee implant. The company hopes those investors will be willing to participate in an IPO sometime in the near future.

ConforMIS’ round stands out because it is the largest round of this still young year. But an analysis of significant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

PathAI Talks PCCPs: ‘Accelerated Software Updates, Saves Time And Money’

 

The US FDA has authorized around 107 devices with Predetermined Change Control Plans in place, with PathAI's AISight Dx digital pathology image management system one of the latest. Medtech Insight talks to Eric Walk, chief medical officer, to find out about the process and its benefits.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Stryker Revises FY25 Tariff Estimate To $175M From $200M As EU Trade Pressures Mount

 
• By 

Kevin Lobo, chairman and CEO of Stryker said that the company is not as exposed to China as others and has manufacturing operations in Europe, influencing the overall tariff impact.

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

More from Business

Additional Death And Injuries Added To 2024 Philips Ventilator Recall

 

Philips Respironics has updated instructions for use for three ventilators that were included in a May 2024 recall. The company also added three potential injuries and one death to the original number.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Stryker Revises FY25 Tariff Estimate To $175M From $200M As EU Trade Pressures Mount

 
• By 

Kevin Lobo, chairman and CEO of Stryker said that the company is not as exposed to China as others and has manufacturing operations in Europe, influencing the overall tariff impact.